Electrophysiologic testing was performed in 31 patients with ventricular tachycardia (21 cases) and fibrillation (10 cases) to characterize the electrophysiologic properties of patients responding or not responding to therapy with class III antiarrhythmic drugs.
patients.
The indications for electrophysiologic study were symptomatic monomorphic sustained ventricular tachycardia (VT) in 21 patients and polymorphic ventricular tachycardia or ventricular fibrillation (VF) in the other 10 patients (Table  I) . Electrophysiologic study: After informed consent was obtained, the electrophysiologic study was performed as described previously. [33] [34] [35] Briefly, the protocol of the induction of ventricular tachyarrhythmia consisted of single and double (triple when necessary) extrastimuli at two cycle lengths, 600 and 400 msec, and incremental pacing at cycle lengths from 667-286msec for 5-15sec at two sites of the right ventricle and a single site of the left ventricle. Stimulation with rectangular pulses of 2msec duration at twice the diastolic threshold was used. If ventricular tachyarrhythmia was not induced, isoproterenol was administered to keep the sinus rate at 20% above the control level and programmed stimulation was repeated. The end-point was either the induction of sustained VT/VF or the completion of the entire protocol. Drug administration:
The stimulation protocol was repeated to evaluate the efficacy of some class III antiarrhythmic drugs after informed consent was obtained from each patient. Nine patients received oral d-sotalol (2 patients) or dlsotalol (7 patients), 15 oral amiodarone, and 7 intravenous E-4031 (4 patients) or MS-551 (3 patients). In this study, there were no patients with complete bundle branch block in the surface electrocardiogram.
The initial dose of d-sotalol was 100 and 200mg per day for 7 days followed by a maintenance dose of 400mg per day for 14 days. The initial dose of dl-sotalol was 80mg and 160mg per day for 7 days followed by the maximal dose of 320mg per day for another 14 days.
The initial daily dosage of amiodarone was 400mg per day for 7 days, followed by a daily maintenance dosage of 200mg per day for 14 days.
E-4031 was administered as a loading infusion of 9mg/kg for 5 minutes with a maintenance dose of 1.6mg/kg per minute during the study.
MS-551 was administered as a loading infusion of 0.3mg/kg for 5 minutes with a maintenance dose of 0.01mg/kg per minute. Definitions: Sustained VT was defined as a VT lasting for 30sec or more, or having to be terminated prior to 30sec because of hemodynamic deterioration. Non-sustained VT was defined as a VT lasting for 6 beats or more that self terminated within 30sec. Ventricular fibrillation (VF) was defined as a tachycardia with irregular cycle lengths and constantly changing surface QRS morphology.
Responders were those in whom neither VT nor VF was inducible to the completion of the entire electrophysiologic study protocol after antiarrhythmic Table  I ).
Effects of class III antiarrhythmic drugs on ventricular tachyarrhythmia: According to the patient selection criteria, 21 patients had induced sustained monomorphic VT and 10 patients had induced polymorphic VT or VF in the control state (C). In the drug-free state, these tachyarrhythmia were induced by a single extrastimulus in 3 patients and ventricular rapid pacing in 3 patients. They were induced before isoproterenol administration in 21 patients and after isoproterenol administration in 10 patients. In 14 of the 31 patients (45%), VT (9 patients) or VF (5 patients) could not be induced by the whole stimulation protocol after class III antiarrhythmic drugs (Table II) . The threshold, the number of extrastimuli, and isoproterenol administration required for tachyarrhythmia induction did not differ significantly between the responders and non-responders. However, the interstimulus coupling interval that induced ventricular tachyarrhythmia (inducing S-S interval) were shorter in Inducing S-S interval=the longest coupling interval (S-S) that induced ventricular tachyarrhythmia; VTCL=ventricular tachycardia cycle length; ISP(-)=before isoproterenol administration; ISP(+)=during isoproterenol administration. disease should be evaluated.
(2) Our observations of the VERP and conduction time reflect the effects of drugs on normal tissue. There might be different electrophysiologic actions between normal and diseased myocardium.41) Thus, it is not possible to extrapolate the drug effects on diseased myocardium in the re-entrant circuit.
(3) The route of antiarrhythmic agent administration was not the same for all patients; the effects of antiarrhythmic agents were assessed following intravenous or oral administration.
(4) Finally, the mechanism by which ventricular tachyarrhythmia inducibility is suppressed is not known. High-mapping resolution at the site of origin of the ventricular tachyarrhythmia might provide a clue, but is possible in only a limited number of cases. Conclusions: The present study focused on the electrophysiologic characteristics that distinguished patients with ventricular tachyarrhythmia who responded to class III antiarrhythmic drugs from those who do not. The responders had more prolonged QT intervals and refractory periods at basic cycle lengths of 600-300msec compared to the non-responders. Among the surface electrocardiographic parameters, the change in QT interval was associated with drug efficacy.
The VERP were more prolonged in the responders and isoproterenol reversed this effect of class III antiarrhythmic drugs, though ventricular tachyarrhythmia remained non-inducible. The precise role of the prolongation of the VERP or QT interval in preventing the inducibility of ventricular tachyarrhythmia needs to be clarified in future studies. 
